Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Matteo S. Carlino, Paolo Antonio Ascierto, Alexander M. Eggermont, Jeffrey E. Gershenwald, Jean Jacques Grob, Axel Hauschild, John M. Kirkwood, Georgina V. Long, Peter Mohr, Caroline Robert, Merrick I. Ross, Richard A. Scolyer, Vernon K. Sondak, Charles Yoon, Andrew Stewart Poklepovic, Piotr Rutkowski, James R. Anderson, Sama Ahsan, Nageatte Ibrahim, Jason J. Luke
Institutions: The University of Sydney, Melanoma Institute Australia, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Université Paris-Saclay, The University of Texas MD Anderson Cancer Center, Aix-Marseille Université, Universitäts Hautklinik Kiel, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Elbe Kliniken Stade-Buxtehude, Institut Gustave Roussy, Royal Prince Alfred Hospital, Moffitt Cancer Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, VCU Massey Comprehensive Cancer Center, The Maria Sklodowska-Curie National Research Institute of Oncology, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Chicago, University of Chicago Medicine Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2947238455